MKI67 and neoplasm: Similarly, DBZ administration rendered PC9OR cell-derived xenograft tumors more sensitive to osimertinib therapy, compared with the control, as measured by tumor growth rate (Fig. 7D), tumor weight (Fig. 7E) and the levels of proliferative marker Ki67 (Fig. 7F).